509 related articles for article (PubMed ID: 28543700)
21. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.
Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT
J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754
[No Abstract] [Full Text] [Related]
22. Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases.
Umemura H; Yamasaki O; Morizane S; Iwatsuki K
Ann Oncol; 2017 Oct; 28(10):2624-2625. PubMed ID: 28651362
[No Abstract] [Full Text] [Related]
23. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
24. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
25. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
26. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
27. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
28. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
29. Melanoma: smart therapeutic strategies in immuno-oncology.
Eggermont AM; Robert C
Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
[No Abstract] [Full Text] [Related]
30. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
31. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
32. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
33. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
34. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
[TBL] [Abstract][Full Text] [Related]
35. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
[TBL] [Abstract][Full Text] [Related]
36. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
37. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
40. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Johnson AS; Crandall H; Dahlman K; Kelley MC
J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
